ALSO NOTED: Abbott's Xience shows well against Boston Sci stent;AstraZeneca nabs new indication for Seroquel

> Abbott Laboratories' waiting-in-the-U.S.-wings stent, Xience, is as safe as and perhaps more effective than the current market leader made by Boston Scientific, according to new data presented at a European conference. Though not yet approved in the U.S., Xience is on the market in Europe. Report | Report

> AstraZeneca got the FDA's blessing to market its antipsychotic Seroquel as an add-on maintenance med for bipolar disorder. Release

> The FDA has eased restrictions on two drugs used to clarify ultrasound images, lifting a ban on administering them to acutely ill patients; Definity and Optison will still carry black-box warnings, however. Report

> Ex-Pfizer CEO Hank McKinnell joined the board of directors at specialty drug- and device-maker Angiotech Pharmaceuticals. Release

> Novo Nordisk got the FDA nod for its new hemophilia treatment NovoSeven RT. Report

> Lundbeck launched its Circadin insomnia drug in Germany. Report

> FDA warned Novartis for omitting the risks of Trileptal, an epilepsy treatment, from a promotional magnet. Report

> GlaxoSmithKline's Indian subsidiary inked a deal to co-promote Daiichi Sankyo's blood pressure remedy Olmesartan and its combo products. Report

> HollisterStier wrapped up two big construction projects that will expand its ability for analytical testing and contract manufacturing. Report

Biotech News

> One of the great pioneers of the British biotech industry, Sir Chris Evans, is fretting that turmoil in the public markets will have a particularly harsh affect on drug discovery work in Europe. Report

> A month after Schering-Plough pulled the plug on its collaboration with Novacea for a new prostate cancer therapy--Asentar--the little biotech company announced that it will cut its work force by more than half. Report

> The little Maryland-based vaccine developer Iomai is being bought out by Intercell for about $189 million. Buyout report

> Vaptans are a new class of drug that target a wide variety of conditions by inhibiting vasopressin, which regulates the circulatory system. Report

> Stem cell researchers at Cornell have genetically engineered a human embryo, a pioneering development that was immediately condemned as a big step toward designing babies. Report

And Finally… Imagine employing a legion of gaming fanatics to channel their obsession into finding solutions to some of the thorniest problems in protein chemistry. That's what biochemist David Baker and a small group of colleagues did in creating Foldit, which challenges gamers to see if they can improve the 3-D structures of proteins. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.